Logo image of INBX

INHIBRX BIOSCIENCES INC (INBX) Stock Fundamental Analysis

NASDAQ:INBX - Nasdaq - US45720N1037 - Common Stock - Currency: USD

12.56  -0.24 (-1.88%)

After market: 12.56 0 (0%)

Fundamental Rating

4

Overall INBX gets a fundamental rating of 4 out of 10. We evaluated INBX against 572 industry peers in the Biotechnology industry. While INBX seems to be doing ok healthwise, there are quite some concerns on its profitability. INBX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year INBX was profitable.
In the past year INBX has reported a negative cash flow from operations.
In the past 5 years INBX always reported negative net income.
INBX had a negative operating cash flow in each of the past 5 years.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

INBX has a Return On Assets of 737.70%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
INBX has a Return On Equity of 919.96%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 737.7%
ROE 919.96%
ROIC N/A
ROA(3y)-60.88%
ROA(5y)-85.92%
ROE(3y)-320.28%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

With an excellent Profit Margin value of 94684.72%, INBX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for INBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 94684.72%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INBX has more shares outstanding
The number of shares outstanding for INBX has been increased compared to 5 years ago.
INBX has a better debt/assets ratio than last year.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

INBX has an Altman-Z score of -2.49. This is a bad value and indicates that INBX is not financially healthy and even has some risk of bankruptcy.
INBX has a Altman-Z score (-2.49) which is in line with its industry peers.
There is no outstanding debt for INBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.49
ROIC/WACCN/A
WACC12%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

INBX has a Current Ratio of 4.70. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.70, INBX is in line with its industry, outperforming 51.51% of the companies in the same industry.
INBX has a Quick Ratio of 4.70. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
INBX has a Quick ratio (4.70) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.7
Quick Ratio 4.7
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 2911.06% over the past year.
Looking at the last year, INBX shows a very strong growth in Revenue. The Revenue has grown by 294.09%.
INBX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -26.86% yearly.
EPS 1Y (TTM)2911.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-158.18%
Revenue 1Y (TTM)294.09%
Revenue growth 3Y-48.12%
Revenue growth 5Y-26.86%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INBX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.85% on average per year.
The Revenue is expected to grow by 325.03% on average over the next years. This is a very strong growth
EPS Next Y2362.97%
EPS Next 2Y-38.05%
EPS Next 3Y-0.73%
EPS Next 5Y11.85%
Revenue Next Year-60%
Revenue Next 2Y-41.42%
Revenue Next 3Y687.22%
Revenue Next 5Y325.03%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.11, the valuation of INBX can be described as very cheap.
Based on the Price/Earnings ratio, INBX is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of INBX to the average of the S&P500 Index (29.63), we can say INBX is valued rather cheaply.
INBX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.11
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y-38.05%
EPS Next 3Y-0.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (2/21/2025, 8:00:01 PM)

After market: 12.56 0 (0%)

12.56

-0.24 (-1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners62.61%
Inst Owner Change-52.08%
Ins Owners15.64%
Ins Owner Change0.49%
Market Cap181.87M
Analysts45.71
Price Target15.3 (21.82%)
Short Float %12.22%
Short Ratio14.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1767.41%
Min EPS beat(2)17.6%
Max EPS beat(2)3517.21%
EPS beat(4)2
Avg EPS beat(4)858.86%
Min EPS beat(4)-63.61%
Max EPS beat(4)3517.21%
EPS beat(8)2
Avg EPS beat(8)422.24%
EPS beat(12)4
Avg EPS beat(12)278.07%
EPS beat(16)8
Avg EPS beat(16)211.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.31%
EPS NY rev (1m)0%
EPS NY rev (3m)9.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.11
Fwd PE N/A
P/S 104.88
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)119.47
EY951.19%
EPS(NY)-9.59
Fwd EYN/A
FCF(TTM)-14.75
FCFYN/A
OCF(TTM)-14.33
OCFYN/A
SpS0.12
BVpS12.33
TBVpS12.33
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 737.7%
ROE 919.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94684.72%
GM N/A
FCFM N/A
ROA(3y)-60.88%
ROA(5y)-85.92%
ROE(3y)-320.28%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 317.55%
Cap/Sales 347.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.7
Quick Ratio 4.7
Altman-Z -2.49
F-Score5
WACC12%
ROIC/WACCN/A
Cap/Depr(3y)171.14%
Cap/Depr(5y)160.56%
Cap/Sales(3y)99.52%
Cap/Sales(5y)64.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2911.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-158.18%
EPS Next Y2362.97%
EPS Next 2Y-38.05%
EPS Next 3Y-0.73%
EPS Next 5Y11.85%
Revenue 1Y (TTM)294.09%
Revenue growth 3Y-48.12%
Revenue growth 5Y-26.86%
Sales Q2Q%N/A
Revenue Next Year-60%
Revenue Next 2Y-41.42%
Revenue Next 3Y687.22%
Revenue Next 5Y325.03%
EBIT growth 1Y-122.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-97.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.35%
OCF growth 3YN/A
OCF growth 5YN/A